Browsing by Author "Oruç Z."

Now showing 1 - 3 of 3
  • No Thumbnail Available
    Item
    Central nervous system metastatic epithelial ovarian cancer. Clinical parameters and prognostic factors: A multicenter study of Anatolian Society of Medical Oncology
    (S.O.G. CANADA Inc., 2017) Seber S.; Turkmen E.; Harputoǧlu H.; Yeşil H.; Arpaci E.; Menekse S.; Pilanci K.; Oruç Z.; Taskovlu B.Y.; Gumusay O.; Aksoy A.; Karaagac M.; Ozarslan E.; Yetisyigit T.
    Central nervous system (CNS) metastasis is a rare event in the course of late stage epithelial ovarian cancer (EOC); however its incidence is increasing in parallel with prolonged survival of patients. Objective: The authors assessed the clinical parameters and potential prognostic features in patients with CNS metastatic disease. Materials and Methods: Clinical data of the 33 patients from the participating centers were retrospectively collected and analyzed. Median age at the time of CNS metastasis was 57 years. Median time from the diagnosis of primary EOC until CNS metastatic disease was 22 months. Nearly half (45.5%) of the patients had single CNS metastatic lesions and all patients in the study group except two received radiotherapy as palliative treatment. Median overall survival (OS) from the time of CNS metastasis was 15 months (0-66). At univariate analysis only number of brain metastatic lesions (p = 0.001) and presence of extracranial disease (p = 0.004) were strongly associated with OS whereas multimodal treatment, size of metastatic lesions, platinum sensitivity, age, grade, and disease stage at presentation were not. Development of CNS metastasis carries a poor prognosis, however patients with single metastatic lesions and only intracranial metastatic disease can have prolonged survival after appropriate palliative management of their disease.
  • No Thumbnail Available
    Item
    The prognostic impact of Her2 status in early triple negative breast cancer: a Turkish Oncology Group (TOG) study
    (Nature Research, 2024) Özyurt N.; Alkan A.; Gülbağcı B.; Seyyar M.; Aydın E.; Şahbazlar M.; Türker M.; Kınıkoğlu O.; Yerlikaya T.; Dinç G.; Aytaç A.; Kalkan Z.; Ebinç S.; Gültürk İ.; Keskinkılıç M.; İşleyen Z.S.; Çağlayan D.; Türkel A.; Şakalar T.; Sekmek S.; Yıldırım N.; Koçak S.; Okutur K.; Özveren A.; Dursun B.; Kitaplı S.; Eren O.Ö.; Beypınar İ.; Hacıbekiroğlu İ.; Çabuk D.; Karaman E.; Acar Ö.; Paydaş S.; Eryılmaz M.K.; Demir B.; Oruç Z.; Yılmaz M.; Biricik F.S.; Salim D.K.; Tanrıverdi Ö.; Doğan M.
    The studies evaluating the impact of Her2 levels in neoadjuvant setting have conflicting data. The aim of the study was to evaluate the prognostic impact of Her2 status in early triple negative breast cancer(TNBC). In the study TNBC patients who were treated with neoadjuvant chemotherapy (NAC) and surgery were analyzed retrospectively. The primary aim of the study was to analyze the impact of Her2 status(Her2-0 and Her2-low) on pathological complete response (pCR). The secondary objectives were disease free survival (DFS) and overall survival (OS). 620 female triple negative breast cancer patients were evaluated. 427 patients (68.9%) had Her2-0 and 193(31.1%) had her2-low pathology. The pCR rates were similar between Her2-0 and Her2-low patients (33.0% vs. 27.5%, p = 0.098). Although Her2-0 group has better DFS (106 vs. 50 months, p = 0.002), in multivariate analysis it had a HR of 0.74 (p = 0.06). In addition, OS was similar (131 vs. 105 months, p = 0.13) with a HR of 0.88 (p = 0.61). In multivariate analysis; presence of LVI (HR:2.2 (95% CI 1.1–3.5) p = 0.001), Clinical stage T1/T2 (HR:0.39 (95% CI 0.2–0.6) p < 0.001) and lymph node negativity (HR:0.35 (95% CI 0.1–0.9) p = 0.03) were independent factors for OS. Although there were pathological and clinical differences, the pCR, DFS and OS were similar between Her2-0 and Her2-low TNBC patients. The importance of Her2 status of TNBC in neoadjuvant setting should be further studied. © The Author(s) 2024.
  • No Thumbnail Available
    Item
    Correction to: The prognostic impact of Her2 status in early triple negative breast cancer: a Turkish Oncology Group (TOG) study (Scientific Reports, (2024), 14, 1, (23556), 10.1038/s41598-024-75293-5)
    (Nature Research, 2025) Özyurt N.; Alkan A.; Gülbağcı B.; Seyyar M.; Aşık E.; Şahbazlar M.; Türker M.; Kınıkoğlu O.; Yerlikaya T.; Dinç G.; Aytaç A.; Kalkan Z.; Ebinç S.; Gültürk İ.; Keskinkılıç M.; İşleyen Z.S.; Çağlayan D.; Türkel A.; Aydın E.; Şakalar T.; Sekmek S.; Yıldırım N.; Koçak S.; Okutur K.; Özveren A.; Dursun B.; Kitaplı S.; Eren O.Ö.; Beypınar İ.; Hacıbekiroğlu İ.; Çabuk D.; Karaman E.; Acar Ö.; Paydaş S.; Eryılmaz M.K.; Demir B.; Oruç Z.; Yılmaz M.; Biricik F.S.; Salim D.K.; Tanrıverdi Ö.; Doğan M.
    Correction to: Scientific Reportshttps://doi.org/10.1038/s41598-024-75293-5, published online 09 October 2024 The original version of this Article contained an error in the spelling of the author Esra Aşık which was incorrectly given as Esra Aydın. The original Article has been corrected. © The Author(s) 2024.